Prangenix

Menu
  • +91 7052295057

Building The Future Of Early Detection & Regenerative Oncology

Prangenix develops multi-disease omics diagnostics and next-generation therapeutics targeting quiescent stem cells — starting with head and neck cancer.

  • Detect
  • Monitor
  • Target
Our Platform
Partner With Us
home-intro-pge-banner

Oncology-Focused Diagnostics & Therapeutic Blueprinting for Personalized Care

Prangenix Therapeutics Pvt. Ltd. is a platform-first biotech company integrating multi-omics diagnostics and therapeutics targeting quiescent cancer stem cells (qCSCs), redefining the future of precision oncology. Headquartered in Eastern Uttar Pradesh, we specialize in liquid biopsy-based solutions for the early detection of head and neck cancers (HNSCC) using cfDNA, cfRNA, miRNA profiling, and AI-driven biomarker discovery. While our near-term focus is on advancing diagnostics, our long-term vision is a scalable, multi-disease platform enabling qCSC-targeted therapeutics through single-cell sequencing, CRISPR, and AI-powered drug discovery. Our mission is to deliver accessible, actionable, and affordable cancer care, empowering clinicians and patients to make earlier, faster, and better treatment decisions.

Two-Track Diagnostic Models

Human Cells

Track 1: Diagnostics (Dx) — Detect. Monitor.

Detect mutations, gene fusions, and epigenetic changes through circulating free DNA (cfDNA) and cfRNA, enabling early-stage detection and monitoring of treatment response without invasive biopsies.

Track 2: Therapeutics (Rx) — Target

Capture cancer stem cells from blood or tissue, apply single-cell sequencing, and create therapeutic blueprints for drug resistance, relapse prediction, and personalized treatment.

Our Expertise in Precision Care

We combine cutting-edge molecular diagnostics with non-invasive technologies to detect cancer signals even before symptoms appear.

Genomic Testing
through Liquid Biopsy

Prangenix performs non-invasive genomic testing using liquid biopsy to detect cancer-specific biomarkers, monitor disease progression, and enable early, accurate, and precision oncology diagnostics for improved patient outcomes.

Identify qCSCs
single cell omnics

Our platform identifies and profiles quiescent cancer stem cells (qCSCs) through single-cell sequencing, providing critical insights for targeted therapeutics and advancing personalized cancer treatment strategies.

Integrated platform
of single cell omnics

Prangenix’s integrated single-cell omics platform combines genomics, transcriptomics, and proteomics with AI-driven analytics to accelerate biomarker discovery, multi-omics diagnostics, and qCSC-targeted therapy development.

Next-Gen Cancer Diagnostics and Therapeutic Blueprinting

At Prangenix Therapeutics, we are building a next-gen platform for modular diagnostics, rare-cell profiling, and therapeutic blueprinting—designed to bring clarity, control, and customization to cancer and chronic disease care. Our goal is simple: make high-resolution molecular insight not only possible, but practical— for researchers, clinicians, and biotech innovators.

Modular Liquid & Tissue Diagnostics

Advanced liquid and tissue-based diagnostic platforms designed to detect early disease biomarkers with high accuracy and reliability.

Rare-Cell & qCSC Profiling

Profiling of rare cells and quiescent cancer stem cells (qCSCs) to understand resistance pathways and enable targeted therapeutic strategies.

Therapeutic Blueprinting

Personalized therapeutic blueprinting through CRISPR designs, CAR constructs, and precision solutions to transform cancer treatment outcomes.

Frequently Asked Questions

1. What is precision oncology?
Precision oncology is a modern approach to cancer care that uses advanced tools like molecular testing and genomic profiling to understand a patient’s cancer at a deeper level. At Prangenix, we use precision oncology to offer tailored diagnostics and treatment guidance for better outcomes.
2. What is a liquid biopsy, and how does it work?
A liquid biopsy is a simple, non-invasive blood test that detects cancer-related markers like cfDNA and cfRNA. It allows early detection and monitoring of cancer without the need for surgical procedures. Prangenix specializes in ultra-sensitive liquid biopsy panels for accurate diagnosis and follow-up.
3. What types of cancers do you focus on?
While we serve all oncology cases, we specialize in head and neck cancers. Our technology platform is being expanded to include other cancers such as oral, lung, gastrointestinal, and more.
4. How does Prangenix help in early cancer detection?
We use advanced molecular diagnostics, including cfDNA, cfRNA, and biomarker analysis, to detect early signals of cancer—even before symptoms appear. This allows for faster diagnosis and proactive treatment planning.
5. Is Prangenix only for hospitals and doctors?
No. Our services are open to everyone—patients, doctors, hospitals, and research institutes. We work with oncologists, ENT specialists, public health programs, and individuals seeking early and accurate cancer diagnostics.
6. What is molecular testing in cancer care?
Molecular testing examines a person’s genes, proteins, and other molecules to identify mutations and abnormalities. This helps doctors choose targeted therapies that are more likely to work for that specific patient. We offer these tests using liquid biopsy and tissue samples.
7. What are qCSCs, and why do they matter?
qCSCs (quiescent cancer stem cells) are rare, dormant cells that often cause cancer relapse and drug resistance. Our Track 2 technology isolates and analyzes these cells to help clinicians plan better, long-term treatment strategies.
8. Why choose Prangenix for cancer diagnostics?
We offer non-invasive, high-precision diagnostics using the latest in liquid biopsy and molecular technology. Our patient-first approach ensures that tests are affordable, accessible, and clinically useful—especially in underserved areas.
9. Can your tests be used to monitor treatment progress?
Yes. Our diagnostics are designed not just for detection but also for tracking how well a treatment is working and checking for early signs of relapse. This helps in adjusting therapies as needed.
10. How can I get tested or collaborate with Prangenix?
You can contact us through our website or by visiting our diagnostics center. We also welcome partnerships with hospitals, doctors, research labs, and biotech companies interested in advancing cancer diagnostics and personalized therapeutics.
Recent News

Read All News

Meddox Are A Medical And Health Department Provider Institutions. Suitable For Healthcare, Medical, Doctor, Dental, Dentist, Pharmacy, Health And Any Related Medical Care Field.
View All Blog
blog1
,
July 22, 2022
No Comments

Spinning Up Multiple WordPress Sites Locally With DevKinsta

A single treatment giving life-long protection from severe allergies such as asthma could be made possible by immunology...

Discover More
blog2
,
July 22, 2022
No Comments

Hormone Therapy the Menopause Transition

Hormonal therapy in menopausal transition: implications for improvement of health-related quality of life. A total of 513 mid-aged...

Discover More
blog3
,
July 22, 2022
No Comments

Diabetes & blood pressure consultation for patients

Interventions targeting hypertension and diabetes mellitus at community and primary healthcare level in low- and middle-income countries:a scoping...

Discover More
blog4
,
July 22, 2022
Comment (1)

Sick Kid? How to Deal with a Child’s Fever

You put your hand on your sick child's forehead. Then the thermometer confirms your suspicion: They've got a...

Discover More

Disclaimer

The information provided on this website is intended for educational and informational purposes only. It should not be considered medical advice. Please consult your doctor or qualified health professional for guidance.